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THE EFFECT OF INDUCED NORMOTHERMIA ON THE OUTCOMES OF 
SEVERE TBI PATIENTS AT BOSTON MEDICAL CENTER 
TUDOR STURZOIU 
ABSTRACT 
The objective of this work was to evaluate the efficacy of an induced 
normothermia protocol by comparing patient mortality and outcomes in patients 
treated at Boston Medical Center (BMC) before and after the implementation of 
the protocol.  The controls (regular fever management) and the cases (induced 
normothermia) were demographically similar, except there were more whites (p = 
0.01) in the control group and more of the patients in the control group were 
transferred to BMC from outside hospitals (p = 0.006), although there was not a 
higher incidence of death among patients who were transferred from outside 
hospitals (p = 0.55).  The patients in the case group were kept normothermic 
throughout the first 7 days of their hospital stay more effectively than those in the 
control group (p = 0.0001).  Average intracranial pressure (ICP) and cerebral 
perfusion pressure (CPP) were not different between the two groups, although 
mean arterial pressure (MAP) was (p = 0.84; p = 0.08; p = 0.02, respectively).  
Mortality was lower in the case group by hospital discharge (p = 0.007) and 
patients in the case group were more likely to achieve a positive functional 
outcome (p = 0.03).  In light of these findings, there is a need for high-quality 
prospective trials to assess the efficacy of induced normothermia compared to 
regular fever management.   
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Introduction 
Traumatic Brain Injury  
Traumatic brain injury (TBI) is one of the major causes of death and long-term 
disability in the United States.  TBIs are responsible for as many as 30% (roughly 
51,000) of injury related deaths, and an estimated 138 people die every day from 
a TBI.  A TBI can be caused by any injury to the head, although not all injuries to 
the head necessarily lead to a TBI (Center for Disease Control, 2014a).  The 
damage done depends on many factors, including the nature of the injury (blunt 
force, twisting, penetrating), the amount of force involved, and the area over 
which the injury occurs (Center for Disease Control, 2014b). TBIs are classified 
as mild, moderate, or severe on the basis of the extent of the deficit that results 
from the injury.  Table 1 presents defining measures that can be used to classify 
the type and severity of a TBI.  
A TBI may lead to long hospital stays, especially in cases where a brain 
hemorrhage occurs, and may also lead to long-term deficits and a necessity for 
long-term medical care from a caregiver.  According to the Center for Disease 
Control (CDC), 2.5 million TBIs occurred in 2010 alone, of which 11.3% resulted 
in hospitalizations (280,000), and roughly 1.7% (50,000) resulted in deaths.  
While the rates of TBI-related Emergency Department (ED) visits increased by 
70% between 2001 and 2010, hospitalizations have only increased by 11%, and 
deaths actually decreased by 7%.  This implies that there has been a large 
increase in the number of TBIs of a mild nature (i.e. those that do not require  
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Classification of a Traumatic Brain Injury (TBI) 
Primary This type of injury occurs at the moment of the initial trauma, 
as when an object strikes the head with a lot of force. 
Secondary This type of injury occurs after the initial insult.  They are 
caused by processes that begin after the initial trauma, 
damaging neurons that were not damaged initially.  
 
Measures of Traumatic Brain Injury Severity 
GCS The Glasgow Coma Scale is used to determine a patient’s 
functional status by assessing their conscious state and 
neurological functions.  Possible scores range from 3-15 and 
are based on motor response, verbal response, and eye 
opening.  This is considered the gold standard for the 
classification of a TBI. Mild: ≥13; Moderate: 8 - 12; Severe: ≤ 8 
LOC Duration Loss of consciousness duration.  Measures severity based on 
how long a patient remains unconscious after the initial trauma.  
Mild - mental status change or LOC < 30 minutes; Moderate - 
mental status change or LOC 30 min to 6 hours; Severe - 
mental status change or LOC > 6 hours.   
PTA Post-traumatic amnesia.  Measures severity based on the 
amount of time that elapses from the initial trauma until the 
moment that a patient can demonstrate a continuous 
awareness of what is occurring around them. 
 
 
 
 
Table 1 – An outline of the ways to classify the type and severity of a TBI.   
(Adapted from Percival et al., 2014 on eMedicine.medscape.com) 
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 hospitalization), a slight increase in TBIs of a serious nature (i.e. those that 
require hospitalization), and overall better management of patients who are 
hospitalized with TBIs (CDC, 2014a, 2014b, 2014c). 
 
The Cost of Traumatic Brain Injury  
The cost, both direct (hospital treatment) and indirect (potential life lost, loss of 
productivity, etc.), of treating TBIs in 2010 was approximately $76.5 billion (CDC, 
2014a).  An overwhelming 90% of this cost is attributed to the direct and indirect 
care and management of severe TBIs, which also account for the vast majority of 
hospitalizations.  While the number or severity of the TBIs that occur cannot be 
directly controlled, there is constantly increasing motivation to improve the quality 
(and even the aggressiveness) of care of patients with TBIs.  This motivation 
stems not only from the economic cost associated with the immediate and long-
term treatment of severe TBIs, but the great psychosocial cost that the outcome 
of treatment has on both the patient and the patient’s family.  There are many 
papers published regarding the estimated direct and indirect economic costs of 
TBI care (Kayani et al., 2009; Runge, 1993; Schulman et al., 2002) and 
estimated cost reduction occurring from a change in this care (Faul et al., 2007; 
Wood et al.,1999; Worthington et al., 2006).  While the papers use different 
criteria, algorithms and models to determine their reported monetary values, the 
ultimate conclusion is the same:  an increase in the quality and aggressiveness 
of care, and, as more recent papers conclude, a closer adherence to the Brain 
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Trauma Foundation (BTF) severe TBI care guidelines, will result in a dramatic 
reduction in the economic cost of severe TBIs.  The BTF guidelines are among 
the foremost sources used for the treatment of severe TBIs, and arguably 
represent the most comprehensive picture of the available literature (up to 2007, 
when the most current guidelines were published).  Using data from 2002, Faul 
et al. (2007) projected the costs of implementing the guidelines on a national 
scale and determined an increase of about 5% ($61 million) to current TBI-care 
medical costs (Faul et al., 2007).  This conservative value encompasses the cost 
of training personnel, performing more laboratory tests, and increasing the 
frequency of intracranial pressure (ICP) monitoring (Faul et al., 2007).  They 
calculated that the estimated savings when taking into account annual medical 
costs, annual rehabilitation costs, and lifetime societal costs would be $3.84 
billion.  This represents an enormous return on the investment required to 
implement and consistently apply the guidelines nationwide.  While there is 
admittedly a lot of possible variation and error in projecting such variables as the 
reduction of patients with a lasting severe deficit, the reduction in mortality, and 
the increase in good outcomes, the conclusion is the same: the widespread 
implementation of the BTF guidelines for the management of severe TBIs will be 
costly and difficult at first, but will lead to a greatly reduced overall economic cost 
of severe TBI.   
While the economic cost of treating TBIs is staggering, the social cost is 
arguably higher.  This is especially true when one takes into account that the 
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long-term deficits following a TBI not only affect the social life of the person being 
cared for, but the lives and the social system of the caregivers.  This idea has 
been looked at since 1974, when Romano published one of the first papers 
looking at the caregiver burden involved in caring for a person with a TBI 
(Romano, 1974).  In 1994, Linn, Allen, and Willer investigated the cognitive and 
emotional changes that occur in TBI survivors and their spouses, who were also 
their caregivers (Linn, Allen, & Willer, 1994).  Their study involved 60 married 
couples at an average of 6 years after the occurrence of the TBI.  Most notably, 
the investigators reported that 70% of the TBI survivors and 73% of their spouses 
reported depression.  Given the amount of time that passed from the initial event, 
it might be surprising to see that depression was still so prevalent, but this is 
likely because the TBI survivors continued to exhibit a large degree of behavioral 
and cognitive deficits (Linn et al., 1994). 
Soon after, in 1998, Marsh et al. conducted two studies that evaluated the 
lives of 69 caregivers at 6 months and 1 year post-severe TBI (Marsh et al., 
1998a, 1998b).  The caregivers were administered questionnaires that gave 
insight to the physical, cognitive, emotional, behavioral, and social states of the 
TBI survivors as well as their own psychological states (Marsh et al., 1998a, 
1998b).  The investigators asked a large array of questions in order to get a 
comprehensive picture.  At month 6, a number of changes in the cognitive 
functioning of the TBI patients were reported, including increased social isolation, 
emotional changes, and physical changes.  The caregivers also reported a wide  
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Table 2 – A summary of the most significant changes in TBI 
patients and their caretakers, as reported by Marsh et al., 1998. 
 (a) 
6 Months Post-TBI, patients  
Measure      Frequency  Distress (1-4) 
Physical Change   83%  3.47 
Cognitive Change   90%  3.34 
Emotional Change   83%  3.39 
Social Isolation   68%  3.49 
 
6 Months Post-TBI, caregivers  
Measure      Frequency  Distress (1-4) 
Time for Myself   73%   3.24  
Anxiety   71%   3.04 
Sleep   62%   2.91 
Social Relationships   55%   2.76 
 
 
(b) 
1 Year Post-TBI, patients  
Measure      Frequency  Distress (1-4) 
Physical Change   87%  3.14 
Cognitive Change   87%  3.14 
Emotional Change   85%  3.41 
Social Isolation   75%  3.14 
 
1 Year Post-TBI, caregivers  
Measure      Frequency  Distress (1-4) 
Time for Myself   60%   3.06 
Anxiety   58%   2.73 
Sleeping Patterns   52%   2.67 
Social Relationships   56%   2.45 
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range of changes in their lives, including having less time for themselves, an 
increase in anxiety, changes in their sleeping patterns, changes in their 
appetites, and an increased use of alcohol and prescription medications in order 
to cope.  The former three were the most common (> 60% reported them) while 
the latter were less common (< 30% reported them).  Section (a) of Table 2 
outlines the most significant changes in the TBI patients and the lives of the 
caregivers, with distress values as calculated by the investigators.  At year 1, 
there was a slight deterioration of the cognitive states of the TBI patients, but a 
slight improvement in the lives of the caregivers. Section (b) of Table 2 
summarizes the values observed at year 1.  Although it is not possible to 
comment on the significance (or lack thereof) of these changes over time 
(because the original authors do not calculate them), one can see that TBI 
survivors as a whole experience an increase in the frequency of reported issues, 
albeit a decrease in the mean distress associated with each issue, and 
caregivers as a whole experience a decrease in the frequency of reported issues 
as well as a decrease in the mean distress associated with these issues.   
There have been a large number of studies done since 1998 on the 
emotional effects of caring for patients with lasting cognitive changes after a TBI 
(and as a result of other traumatic events), but they have not shown an obvious 
shift in the way that caregivers are affected.  In 2000, Douglas and Spellacy 
investigated the psychological states of 35 TBI survivors and their caretakers 
(Douglas & Spellacy, 2000).  They determined that 57% of TBI survivors and 
7 
 
60% of their caregivers could be classified as clinically depressed.  Jumping 
almost a decade into the future, in 2009, Kreutzer et al. examined a group of 273 
caregivers and determined that only as many as 24% of them exceeded cutoffs 
for clinical depression on the scale that they used in the study (Kreutzer et al., 
2009).  Caregivers also experienced other kinds of emotional distress, and some 
experienced multiple forms simultaneously, but 66% of caregivers did not exceed 
cutoffs for any of the scales of emotional distress used.  This result looks 
promising, but the results do not fit perfectly into the context of this work because 
the study examined both “moderate” and “severe” TBI survivors.  It is possible to 
presume from these results, though, that functional outcome is an important 
predictor of caregiver and family distress.  Survivors of moderate TBIs are more 
likely to have a good outcome than survivors of severe TBIs (Hellawell et al., 
1999), so the lower prevalence of emotional distress in this study could be 
explained by the better overall outcomes of the patients whom the caregivers 
were caring for.  Indeed, a number of studies corroborate the contention that the 
presence of cognitive and social changes in TBI survivors are the most stressful 
aspects of the TBI for their caregivers and families (Ponsford et al., 2003).  While 
there is no clear trend in how caregivers and their families are being affected by 
post-TBI care over time, it is clear that emotional distress is very prevalent in this 
population.   
 A long time has been spent outlining the costs of TBI in order to 
demonstrate that there is a great motivation, economically, and socially, for 
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treating severe TBIs more effectively in order to maximize positive outcomes for 
patients.  Many advances have been made on the front of family-centered care, 
and support is generally no further than a click away, but the best way to target 
the costs of severe TBI care is to improve functional outcomes so that costly 
post-TBI care is as necessary.  
 
Secondary Injuries and Hyperthermia 
Secondary injuries, or those which are not caused by the initial trauma, pose a 
great threat to TBI patients’ outcomes.  Secondary injury begins almost 
immediately after primary injury and is mediated by a number of factors, including 
inflammation and hypothalamic disturbances (Thompson et al., 2003; Werner & 
Engelhard, 2007).  These, as well as other processes, can lead to an increase in 
body, and more critically, brain temperature, causing persistent fever.  Fever in 
TBI is associated with increased morbidity and mortality and poorer outcomes 
(Badjatia, 2009; Greer et al., 2008 for meta-analysis), which is an issue because 
fever is very common.  One of the problems with targeting fever is that it is not 
immediately clear whether it is due to a secondary infectious process or is a 
byproduct of the injury.  Inflammatory responses and cellular damage 
immediately follow a TBI, thus leading to an increase in temperature, but 
secondary infection is also common after a TBI and is even more likely in cases 
of TBIs caused by penetrating injuries (Anthony & Couch, 2014).  This is 
important mainly because the methods that would be used to treat an infectious 
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fever and a non-infectious fever are very different (Provencio & Badjatia, 2014).  
The remainder of this introduction will focus on elucidating some of the 
mechanisms behind hyperthermia of a non-bacterial etiology. 
Normally, the brain is partitioned away from the peripheral immune system 
by way of the blood-brain-barrier (BBB).  After a traumatic brain injury, the BBB is 
disrupted, allowing immune molecules from the peripheral immune system into 
the brain (Mrozek et al., 2012; Thompson et al., 2003).  Inflammation is rapid and 
is thought to result from the compounding effects of blood and blood products, 
broken down tissue, and other byproducts of the primary damage, as well as the 
rush of immune cells coming in to clean up after the damage.  Inflammation is an 
adaptive response to injury that is meant to help the body eventually heal itself, 
but in the case of traumatic brain injury, it is regarded as doing more harm than 
good (Thompson et al., 2003).  One of the main negative effects of inflammation 
in the case of TBI is that it causes generalized fever.  Hyperthermia that occurs 
beyond the acute phase is most likely accomplished by the release of pyrogenic 
cytokines in the acute phase that lead to prostaglandin E2 (PGE2) production, 
which causes a sustained febrile response (Thompson et al., 2003).   
Hypothalamic disturbances are another cause of increased temperature in 
TBI patients.  The hypothalamus is the body’s temperature regulation center, and 
it has a specific set-point, much like a thermostat (Thompson et al., 2003).  It 
contains temperature sensitive neurons that determine the body’s temperature 
both by monitoring it themselves and by receiving input from peripheral sites.  
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After brain injury, prostaglandins can cross the BBB and strongly activate 
temperature-sensitive neurons, which in turn activate heat conservation 
mechanisms and cause the hypothalamus to raise the set-point.  The 
hypothalamus can also malfunction if it is damaged directly in the initial trauma or 
if secondary injury occurs to it.  In cases in which the hypothalamus itself is 
damaged, it may not act to reduce the body temperature when the set-point is 
reached, or it may even directly alter the set-point.  In 1971, Crompton reported 
that 42.5% of the cadavers of patients with TBI on which he performed autopsies 
had hypothalamic damage (Crompton, 1971).     
So far, a number of mechanisms that may lead to TBI have been outlined.  
Why, though, does hyperthermia so profoundly impact outcome in TBI?  Fever is 
not uncommon in humans – after all, it is one of the body’s primary responses to 
infection.  It is now believed that the negative effects of fever in TBI result 
because it is the wrong time for fever, so to speak (Thompson et al., 2003).  In 
the acute phase of TBI, immediately following the initial injury, a large number of 
variables are changing and the brain is faced with either an excess or a lack of a 
number of the things that it needs, like oxygen and glucose.  Metabolism is 
affected, the energy supply is affected, and generalized inflammation from 
immune processes is running rampant - an increased temperature exacerbates 
all of the acute demands already being placed on the body. 
Two of the largest causes of secondary injury related to hyperthermia 
result from mitochondrial damage (Soustiel & Larisch, 2010; Werner & 
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Engelhard, 2007) and from neuronal over-excitation, leading to excitotoxicity 
(Cheng et al., 2012; Werner & Engelhard, 2007).  Heat stress quickly leads to 
mitochondrial dysfunction.  One of the ways in which dysfunction occurs is in the 
heat-induced release of cytochrome c from mitochondria (Stoica & Faden, 2010; 
White et al., 2007).  This has many implications.  For one, cytochrome c is an 
essential part of the electron transport chain, which is fundamental to aerobic 
respiration, and without it, respiration is not as efficient.  In addition to reducing 
the efficiency of aerobic respiration, the absence of cytochrome c can actually 
lead to a decoupling of energy metabolism through the disruption of the proton 
gradient.  This can essentially transform mitochondria into heat generators 
(Mrozek et al., 2012).  Additionally, cytochrome c is an important factor in 
neuronal apoptosis.  It is one of the molecular factors that, once activated as part 
of an apoptotic cascade, will eventually be a component of an apoptosome (an 
initiator of apoptosis).  This apoptosome eventually activates a protein called 
caspase-9, which activates caspase-3, a critical effector of neuronal apoptosis 
(Cheng et al., 2012).  This decoupling may also lead to an increased production 
of reactive oxygen species, more commonly known as free radicals.  Free 
radicals cause cellular damage through a number of mechanisms, including an 
exacerbation of mitochondrial dysfunction (White et al., 2007) and damage to 
DNA, which can itself induce apoptosis on a large scale. 
The other mechanism, neuronal over-excitation, is related to the dramatic 
increase in glutamate that occurs after a TBI (Weber, 2012).  Glutamate is the 
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primary excitatory molecule in the brain.  In TBI, as well as in stroke, glutamate is 
released in enormous quantities from the neurons in the area of the primary 
insult (Thompson et al., 2003; Werner & Engelhard, 2007).  It then radiates 
outward and causes rampant activation of neurons in its wake.  For this reason, 
some researchers have ventured as far as to call TBI an excitotoxic injury to the 
brain (Palmer et al., 1993), and a disease process as opposed to an event 
(Masel & DeWitt, 2010).  The main consequence of such prolific glutamate 
signaling, and the mechanism by which neuronal damage is mediated, is the 
flood of calcium ions from the cytosol into neurons (Weber, 2012).  Elevated 
levels of intracellular calcium lead to neuronal damage through a number of 
pathways.  First, a number of calpains (which are cysteine proteases) are 
released by high levels of calcium - the levels of calcium that are thought to be 
reached after a TBI (Weber, 2012).  Many proteins and essential cellular 
components serve as substrates for and are broken down by calpains, including 
a large array of cytoskeletal components, cell adhesion molecules, and even 
glutamate transporters and receptors (Weber, 2012; White et al., 2007).  Calpain-
mediated damage to these components can compromise the structural integrity 
of affected cells, which leads to an increase in membrane permeability to ions 
and even to macromolecules (Weber, 2009).  Increased intracellular calcium also 
induces the activation of caspases.  As has been previously discussed, caspases 
are involved in the activation of an apoptotic cascade.  This effect is likely 
compounded with the effect that results from the apoptosome created through 
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mitochondrial damage (Cheng et al., 2012; Stoica & Faden, 2010).  Increased 
intracellular calcium can also lead to an increase in nitric oxide through the 
activation of nitric oxide synthase, which is regulated by calmodulin, a protein 
whose activity is increased by increasing levels of calcium (Weber, 2012).  While 
nitric oxide is a physiologically essential molecule in low concentrations, it 
becomes toxic in high concentrations due to its ability to form toxic reactive 
oxygen species (Weber, 2012).   
There is an appreciable amount of overlap between the damage done 
through mitochondrial breakdown and that done through glutamate over-
excitation.  This is perhaps why damage on these fronts is so difficult to control – 
because their mediators are coming from all directions.  It should come as no 
surprise that another one of glutamate’s excitotoxic effects stems from its ability 
to overload mitochondria.  Overload is primarily mediated by the induction of the 
inner-membrane-bound mitochondrial permeability transition pore (MPTP) and 
can also be mediated and exacerbated by oxidative stress.  The former ruins the 
proton gradient and reduces the effectiveness of or halts cellular respiration, and 
the latter can eventually lead to swelling capable of bursting the mitochondrion 
(Soustiel & Larisch, 2010).  Again, overlap can be seen between the damage 
done by heat stress and the damage done by over-excitation.  Compounded, the 
two lead to rampant secondary cellular damage.   
Although they are not the only ones, the above mechanisms are the main 
mechanisms by which an increase in temperature mediates secondary neuronal 
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damage.  New therapies such as inducing an over-expression of the glutamate 
transporter or mimicking anti-apoptotic proteins (Harvey et al., 2011; Soustiel & 
Larisch, 2010) aimed at mitigating the damage done by the aforementioned 
mechanisms are constantly being looked into, but progress on pharmacological 
fronts is slow.  As such, there is a lot of research interest regarding the clinical 
application of temperature control during hospitalization, and its effects on 
cellular damage and eventual functional outcome.   
 
Therapeutic Hypothermia  
 In 1945, Fay reported on the neuroprotective effects of therapeutic hypothermia 
in severe TBI (Fay, 1945).  Ever since, many studies have been done on the 
effects of therapeutic hypothermia on the course of treatment and the outcomes 
of patients with TBIs.  Two landmark studies on the use of therapeutic 
hypothermia (in cardiac arrest) were published in 2002, in the same edition of the 
New England Journal of Medicine (Bernard et al., 2002; The Hypothermia After 
Cardiac Arrest Group, 2002).  The first, published by The Hypothermia After 
Cardiac Arrest Group, studied the efficacy of mild systemic hypothermia in 
improving neurological outcomes after an out of hospital cardiac cause by 
ventricular fibrillation (The Hypothermia After Cardiac Arrest Study Group, 2002).  
The time to target temperature (32oC - 34oC, or 89.6oF - 93.2oF) was, on 
average, 8 hours, and patients remained in this range for 24 hours before being 
rewarmed slowly for 8 hours.  Patients (n = 275) were assigned randomly to 
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normothermic temperature management (i.e., standard of care) or therapeutic 
hypothermia.  55% of the patients in the hypothermia group and 39% of the 
patients in the standard of care group had a favorable neurologic outcome at 6 
months, as defined by a 1 (good recovery) or a 2 (moderate disability) on the 
Cerebral Performance Category scale.  The rate of death was 14% lower in 
patients assigned to the hypothermia group as compared to the normothermia 
group.  The authors concluded that 6 patients would need to be treated with 
therapeutic hypothermia under their protocol in order to prevent 1 unfavorable 
neurologic outcome (95% confidence interval [CI], 4 to 25).  One of the limitations 
of the study was stated to be the fact that it was not feasible to blind the 
attending physicians.  Studies in which treatment allocation is not concealed may 
exaggerate the effect of a treatment (Akobeng, 2005).  The second study, 
published by Bernard et al. also used patients with out of hospital cardiac arrests 
caused by ventricular fibrillation, except their patient population remained 
comatose after resuscitation (Bernard et al., 2002).  Patients (n = 77) were 
randomly assigned to therapeutic hypothermia or normothermia (i.e., standard of 
care).  The differences between the cooling protocol in this study and the 
aforementioned study are that the time to target temperature (33oC, or 91.4oF) 
was 2 hours, and the treatment was only maintained for 12 hours, with 
rewarming taking place over 6 hours.  Patients in the hypothermia group had a 
significantly better outcome than patients in the normothermia group (49% to 
26%, p = 0.046).  A patient was considered to have a good outcome if he/she 
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was discharged home, and a poor outcome if he/she died in the hospital or was 
discharged to a nursing facility.  There was no significant difference in mortality 
between the two groups, though that statement is only valid during the hospital 
stay, as patients were not assessed after being discharged.  These two papers 
immediately generated discussion amongst physicians regarding the 
implementation of therapeutic hypothermia as a standard of care, and they 
became landmark studies in the field.  As previously mentioned, therapeutic 
hypothermia has been a treatment option since the 1950s, with its efficacy in 
cardiac arrest only being truly established with randomized controlled trials in 
2002.  Even so, the results of these trials cannot be generalized outside of 
improving outcomes in cardiac arrest caused by ventricular fibrillation.  Indeed, 
there have been a large number of papers published examining the effect of 
therapeutic hypothermia on outcomes in patients with TBI, and while a number of 
them show that there may be benefits, they are generally either small or poor-
quality trials (see Sydenham, Roberts, & Alderson, 2009 for review of 
hypothermia trial quality).  In a Cochrane review published in 2009, which pooled 
together 23 randomized controlled trials assessing therapeutic hypothermia, the 
authors concluded that the evidence is not strong enough to conclude that 
hypothermia is beneficial in the treatment of head injury (Sydenham et al., 2009).  
They go on to reaffirm that there was no shortage of trials that showed that there 
might be a positive effect of therapeutic hypothermia on outcome in TBI patients, 
but all of the studies that they reviewed that made this claim were of poor quality 
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and unlikely to be generalizable.  In 2013, Georgiou and Manara published a 
literature review of 18 randomized controlled trials involving 1851 patients 
(Georgiou & Manara, 2013).  Trials were graded using the GRADE (Grading of 
Recommendation Assessment, Development, and Evaluation) system, an 
increasingly utilized grading system that attempts to standardize how trial quality 
and recommendation strength are determined and stated.  All (100%) of the 
moderate and high quality trials reported no benefit of therapeutic hypothermia, 
while a number of the low and very low quality trials reported a benefit.  The low 
quality trials were poor for widely differing reasons, but generally, some very 
important detail was either not reported or not carried out correctly as part of the 
protocol (Georgiou & Manara, 2013).  In 2014, Crossley et al. published another 
literature review examining 20 trials involving a total of 1885 patients (Crossley et 
al., 2014).  Although the authors concluded that the trend of the studies reviewed 
pointed towards reduced rates of death and long-term disability in TBI patients 
treated with therapeutic hypothermia, they acknowledge the inherent weakness 
of the generally poorly conceived trials and therefore recommend the need for 
larger, higher quality randomized controlled trials before a definitive 
recommendation can be made.  The lack of consistency in the data coupled with 
a lack of quality trials are the primary reasons that therapeutic hypothermia has 
not become the standard of care in traumatic brain injury as it has in v-fib cardiac 
arrest.   Even in the field of cardiology, the benefits of therapeutic hypothermia 
are questionable when they are examined outside of the context of cardiac arrest 
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caused by ventricular fibrillation.  In a large international trial including 950 
patients, Nielsen et al. (2013) demonstrated that therapeutic hypothermia to 33oC 
(91.4oF) did not offer any benefit in outcome (as measured by the patients’ 
modified Rankin Scale and Cerebral Performance Category) compared to 
managing temperature to 36oC (96.8oF) (Nielsen et al., 2013).  Even though the 
first monitored heart rhythm in the majority (~75%) of the patients they 
randomized into the trial was ventricular fibrillation, it is possible that the 
outcomes of that subset of patients was better and that the data was skewed by 
the 25% whose cardiac arrests were not caused by ventricular fibrillation.  This 
study is also significantly larger than the 2002 studies, though, so it is also 
possible that the larger sample size is providing a more accurate assessment of 
the question.  Regardless of the reason, as of late, it is clear that therapeutic 
hypothermia may not be as beneficial on a large scale as was previously thought. 
Given the uncertainty surrounding therapeutic hypothermia as a treatment, there 
is a push for alternate temperature management strategies.   
 
Induced Normothermia 
One of the alternative management strategies, induced normothermia, involves 
keeping a patient’s temperature around normal body temperature (97.5oF – 
99.5oF) at all times during treatment.  Attempts to maintain normothermia can be 
in pharmacologic or non-pharmacologic form.  Induced normothermia is, in 
theory, a less intrusive management strategy than therapeutic hypothermia due 
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to the fact that it does not require non-physiological temperatures to be achieved.  
As such, it presents less risks to patient well-being and is associated with fewer 
possible complications.  Additionally, some of the complications that can occur 
with hypothermia, such as electrolyte imbalances and increased incidence of 
sepsis and pneumonia, among others, which will be discussed in more detail 
later, can be avoided with induced normothermia.  Even so, it still may still 
require considerable pharmacological intervention, and as such, it is not a benign 
treatment (Choi et al., 2011; Parra, 2012).  Reducing fever in TBI patients is not 
as straightforward or simple as one might initially believe, and so relatively large 
doses of the drugs that are utilized for the purpose of maintaining normothermia 
may be used, such as anti-pyretics, muscle relaxants, and anti-shivering 
medications (Choi et al., 2011; Mahmood & Zweifler, 2007; Parra, 2012).  There 
are a number of considerations that must be made with this key point in mind.  
First, the drugs that are used, the amount of drug being administering, and the 
effects that those drugs in those quantities might have on the patient must be 
considered.  Second, it would be prudent to consider the cost associated with 
very aggressive treatment when it is weighed against the returns in patient 
outcome.  These questions are as of yet, unanswered.  
One aspect of therapeutic hypothermia and induced normothermia that 
has not yet been touched upon is that of shivering.  The other mechanism, 
vasoconstriction, which comes before shivering, will be briefly discussed in the 
following paragraph.  A focus on shivering is important because the implications 
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• Dexmedetomidine 
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Tier 1 
• Dexmedetomidine 
hourly based no weight, 
no loading dose  
            AND/OR 
• Meperidine q4h 
 
Tier 1 
• Propofol based on 
weight  
Tier 2 
Propofol based on weight 
Tier 2 
• Dexmedetomidine 
hourly based no 
weight, no loading 
dose 
          AND/OR 
• Meperidine q4h 
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Patient on Induced Normothermia Protocol 
Figure 1 – Flow 
chart outlining 
Boston Medical 
Center’s 
normothermia 
protocol.  
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for patient care in an ICU setting are very serious (Choi et al., 2011).  Boston 
Medical Center’s anti-shivering guidelines are outlined in highly simplified form in 
Figure 1 (Boston Medical Center, 2012). 
Shivering is one of the body’s main mechanisms for regulating its 
temperature in the event of a large change in core temperature.  It involves 
involuntary contraction of skeletal muscles with the goal of producing warmth and 
increasing the body’s temperature (Parra, 2012).  The shivering threshold for 
humans is around 35.5oC (95.9oF), although elderly patients have a shivering 
threshold about 1o lower.  Shivering can cause as much as a 500% increase in 
metabolic demand short-term, and as much as a 200% increase in metabolic 
demand if shivering is sustained long-term (Parra, 2012).  While shivering is 
generally a protective process, it is one that should be avoided in a clinical 
setting mainly because it has been shown to significantly reduce brain tissue 
oxygenation in patients with a severe TBI (Eriksson et al., 2012; Oddo et al., 
2010).  This decrease in oxygenation has been shown to be highly correlated 
with the intensity of cooling, as one might expect.  This decrease in brain tissue 
oxygenation is mainly attributed to the increase in metabolic demand and the 
following increase in oxygen consumption to keep up with that demand, on a 
whole-body scale (Oddo et al., 2010).  Optimal brain oxygenation is vital 
especially immediately following a TBI, when mitochondrial dysfunction and 
cytotoxic edema can exacerbate the negative effects that would normally be 
expected from a lack of oxygen.  Optimal oxygenation becomes even more vital 
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when considering that the negative effects of reduced cerebral oxygenation can 
occur even when oxygenation is only slightly decreased (Cheng et al., 2012; 
Eriksson et al., 2012; Maas et al., 2008).  There have been many studies on the 
effects of brain oxygenation in severe TBI patients, and the majority of them have 
shown that reduced brain tissue oxygenation is related to increased mortality and 
poorer outcomes (Dings et al., 1998; Eriksson et al., 2012; McCarthy et al., 2009; 
Narotam et al., 2009; Spiotta et al., 2010; Stiefel et al., 2005).  In light of these 
findings, the normothermia guidelines were developed with the intention of 
maintaining a patient’s temperature around normal with the use of cooling pads 
and pharmacologic treatments, while aggressively preventing the shivering that 
may result from the intervention.   
As part of the normothermia protocol, cooling pads and advanced cooling 
pads (Arctic Sun®) are used to bring a patient’s temperature down.  Generalized 
cooling pads are first in line, but they are not generally very effective against 
persistent fever (Polderman & Herold, 2009).  Arctic Sun® is a much more 
advanced temperature management system that consists of specialized pads 
that wrap around a patient’s thighs and thorax.  The water in the pads is cycled 
through a machine that cools the water to the extent that is needed in order to 
keep the patient at the specified temperature (as measured through a foley or an 
esophageal probe).  The temperature of the water that is cycling through the 
system can be monitored in order to assess how difficult it is to keep a patient at 
the specified temperature.  If the temperature of the water dips dramatically, it 
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implies that the patient is difficult to cool, and this could indicate an infectious 
process.  The downside of cooling pads are that they increase the risk of skin 
ischemia and necrosis when used for long periods of time due to vasoconstriction 
(Medivance, webpage), which is an innate defense mechanism that prevents the 
loss of heat from the body’s core by shunting blood flow away from the skin 
(Parra, 2012). 
Acetaminophen is the first drug given to any patient whose temperature is 
above 38oC for more than 2 hours.  In this application, it is intended to stem their 
fever.  The mechanism by which acetaminophen produces its antipyretic effects 
is still undefined, despite its universal use for this purpose, although part of its 
mechanism of action may involve reducing levels of PGE2 (Buck, 2011).  There 
are not many side effects of acetaminophen, and the more common ones, like 
nausea and stomach pain are unlikely to immediately affect a patient who is 
undergoing care for a severe TBI (due to very likely being unconscious).  While it 
is generally considered safe if used at the therapeutic threshold (< 4 grams/day), 
recent studies have demonstrated that long-term use (7-13 weeks and beyond) is 
associated with an increase in platelet count, a decrease in hemoglobin, and a 
reduction in mean red cell volume (Doherty et al., 2011).  The authors attributed 
the reduction in hemoglobin to occult gastrointestinal bleeding rather than to 
another mechanism, such as hemodilution (Doherty et al., 2011).  This is an 
interesting finding because this is not a usual side effect of acetaminophen.  
While this study was primarily looking at acetaminophen prescribed for chronic 
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knee pain, the findings on long-term effects can likely be applied more broadly.  It 
is not unheard of for patients to be in the ICU for the treatment of a TBI for 2 
months or longer, so this is a possible side effect that should be kept in mind.   
Buspirone is given prophylactically to all patients being treated under the 
normothermia protocol in order to prevent shivering (Boston Medical Center, 
2012).  Buspirone is a partial serotonin antagonist at the 5-HT1A serotonin 
receptor (Mahmood & Zweifler, 2007).  Alone, it slightly reduces the shivering 
threshold (although it is more effective when used with another drug than when 
alone).  Its side effects include dizziness and headache, which, like those of 
acetaminophen, are not likely to immediately impact a patient being treated for a 
severe TBI.  It has been demonstrated to be safe for long-term use, although the 
population in which it was studied long-term (up to a year) was taking buspirone 
for the purpose of treating anxiety (Feighner, 1987; Rakel, 1990).  Again, while 
these studies were not done in the population of interest, the results are likely to 
be able to be generalized.   
Magnesium sulfate is also given prophylactically in order to prevent 
shivering.  It is an N-methyl-D-aspartate (NMDA) receptor antagonist and that 
reduces the shivering threshold (Wadhwa et al., 2005) and induces vasodilation 
at the level of the skin (Badjatia, 2009).  It has also been shown that low serum 
magnesium is independently associated with shivering, and so it is also used 
with the goal of maintaining an adequate serum concentration (Badjatia et al., 
2008).  Its side effects include flushing and hypotension.  Because the vital signs 
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of severe TBI patients are already monitored very closely in the ICU, there is not 
an enormous amount of concern that a drop in blood pressure will go missed or 
persist for very long (because it will be addressed in a timely manner), but this 
possible side effect should be kept in mind.   
Surface warming with the BairHugger® surface warmer is also done 
prophylactically in order to prevent shivering.  The idea behind this therapy is that 
temperature receptors on the skin will be warmed to the point that they send 
signals that inhibit shivering to the brain (Badjatia, 2009).  There are no side 
effects from surface warming.   
If prophylactic treatment is not successful and the patient begins to shiver, 
patients that are not intubated or are intubated but do not require sedation are 
given dexmedetomidine and/or meperidine (Boston Medical Center, 2012).  If a 
patient receives the maximum doses of both dexmedetomidine and meperidine 
and continues to shiver, they receive propofol.  Patients who are intubated and 
sedated receive these in the opposite order - propofol and then 
dexmedetomidine and/or meperidine.  Dexmedetomidine is an alpha-2 
adrenergic agonist that causes vasodilation and lowers the shivering threshold 
(Talke et al., 1997).  It has been shown to be safe for long-term use, with the 
incidence of hypotension, hypertension, and bradycardia being the same as 
during short term use in critically ill patients (Ozaki et al., 2014).  Meperidine is an 
opioid agonist and an NMDA antagonist (Parra, 2012).  In clinical settings, it is 
mainly used to relieve pain and prevent shivering by lowering the threshold.  It 
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works synergistically with both dexmedetomidine and buspirone, greatly 
increasing their efficacy (Badjatia, 2009; Doufas et al., 2003; Mahmood & 
Zweifler, 2007).  It is generally very effective as a last resort for reducing 
shivering because of these synergistic interactions.  It has a larger side effect 
profile than the rest of the drugs in the normothermia protocol.  Some, like 
nausea, dry mouth, and flushing, are unlikely to cause immediate distress to a 
severe TBI patient.  Others, like vomiting, constipation, and respiratory 
depression can complicate treatment.  As it is an opiate, it is not recommended 
for long-term use, and can even induce seizures when administered for long 
periods of time (Mahmood & Zweifler, 2007). 
Regarding the second point above, in general, it is reasonable to advocate 
for management that is as aggressive as is needed, because while it might cost 
more in the present, the lifetime savings from a possible improvement are likely 
to outweigh the immediate increase in cost.  The case here is similar to that of 
aggressive management of ICP in TBI (see page 3).   
 
Purpose 
To summarize, there are a number of reasons why it may be beneficial to treat 
patients with induced normothermia as opposed to therapeutic hypothermia.  
Among these reasons are: 
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1. Shivering.  In one study, shivering was recorded in only 30% of patients 
being treated with normothermia, while being recorded in 70% of patients 
being treated with hypothermia (Kiekkas et al., 2005). 
2. Coagulopathies.  It has been demonstrated that the coagulation cascade 
is inhibited by hypothermia, which raises the concern for an increased 
chance for hemorrhage, among other things (Broessner et al., 2012; 
Rohrer & Natale, 1992; Rubiano et al., 2013).     
3. Rewarming injury.  Improper rewarming after treatment with therapeutic 
hypothermia is complete can offset any benefit of therapeutic hypothermia 
as well as introduce novel injuries by mechanisms that are not completely 
understood (Broessner et al., 2012; López-Messa & Andrés-Dellano, 
2010). 
4. Electrolyte imbalance.  Electrolyte imbalances are common, and they 
result from hypothermia induced tubular dysfunction that leads to 
increased diuresis (Nielsen et al., 2009; Polderman et al., 2001)  
5. Increased risk of sepsis and pneumonia.  Owing to its impairment of 
immune functions, hypothermia has been said to increase the chance of 
secondary infection (Polderman & Herold, 2009).  A recent meta-analysis 
concluded that there is a connection between hypothermia and an 
increased risk of sepsis and pneumonia, but no increase in the overall risk 
of infection. although this could have been due to the heterogeneity in the 
lowest temperature reached during cooling; it is possible that sepsis and 
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pneumonia can be seen at higher temperatures within the hypothermic 
range than other infections (Geurts et al., 2014). 
 
Ultimately, the purpose of this work is to attempt to provide an answer 
regarding the effectiveness of aggressive normothermia by comparing patients 
who were cared for before the protocol was instituted to patients who were cared 
for after the protocol was instituted.  To reach that end, the efficacy of aggressive 
treatment in reducing body temperatures during the first seven days of patients’ 
ICU stays will be examined, as will how other variables (such as intracranial 
pressure and mean arterial pressure) are affected by this management and 
whether or not the treatment is associated with an improvement in patient 
outcome as measured by the modified Rankin Scale.   
 
Methods 
Study Design 
In order to assess the efficacy of aggressive induced normothermia in 
maintaining patient temperature throughout their ICU stay, a retrospective case-
controlled study was designed.   
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Control Group 
The control group consisted of severe TBI patients who were treated at Boston 
Medical Center between June 2009 and December 2010, before the 
implementation of the induced normothermia protocol.   
Case Group 
The case group consists of severe TBI patients who were treated at Boston 
Medical Center between June 2012 and December 2013.  During this time 
period, the induced normothermia protocol was already in place.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial extraction of all TBI cases from ICU log; June 2009 – 
December 2010, June 2012 – December 2013 
 
 
 
 
Further extraction of all cases with GCS ≤ 8 in  
ED note, H&P, or admission note 
Further extraction of all cases 
whose notes specified they 
were on the normothermia 
protocol 
 
Controls, receiving 
only regular 
temperature 
management 
Cases, receiving aggressive 
normothermic temperature 
management 
 
      Severe TBI cases  
      from June 2012 to 
      December 2013 
      Severe TBI cases  
      from June 2009 to 
      December 2010 
 
Figure 2 – Flow 
chart detailing 
the method by 
which the 
controls and the 
cases were 
determined.  
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Table 3 – A list of all of the variables that were extracted from the EMR of each 
patient. 
All of the data used in the final analysis were extracted from the EMRs of patients 
who were treated at Boston Medical Center in two date ranges: June 2009 – 
December 2010 and June 2012 – December 2013.  All TBI cases were initially 
extracted from a log of the patients treated in the ICU during those two date 
ranges who carried a diagnosis of TBI.  Once the list was complete, each 
patient’s EMR was reviewed and every Glasgow Coma Scale (GCS) score that 
was calculated for the patient in their emergency department (ED) note, history & 
physical (H&P) note, and admission notes was recorded.  All of these notes were 
written within 12 hours of the patient arriving in the ED.  If a patient’s GCS was ≤ 
8 (indicating a severe TBI) in any of the three notes, the patient was included in 
the study sample.   
1. GCS – lowest and highest score recorded each day.
2. Intubation status
o Along with the time of extubation, if available
3. First white blood cell count of the day
4. Hourly temperature
o Source of the temperature measurement
5. Mannitol use
6. 3% hypertonic saline use
7. 23.4% hypertonic saline use
8. Arctic Sun® use
o High and low water temperatures
9. Tylenol use
10. Buspar use
11. Demerol use
12. Hourly MAP
13. Hourly ICP
14. Hourly CPP
Variables extracted during days 1-7 of each patient’s ICU stay 
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Variables  
Data was extracted from the first seven days of every patient’s ICU stay.  Every  
variable that was examined was recorded for every day.  The following section  
reviews the significance of every variable along with a reason for recording each 
one, in the order that they are presented in Table 3. 
The GCS score is used universally as a marker of a patient’s 
consciousness.  Despite being over 40 years old, it remains a standard in the 
field (Teasdale et al., 2014).  GCS is significant to track in the ICU because when 
looking at raw data, it is the most solid indicator of day-to-day improvement in 
neurological functions.  Intubation status was recorded because being extubated 
while the ICU is a marker of progress.  WBCs were tracked because fever is 
common in TBI patients, and it is important to be able to distinguish, within 
reason, between a fever caused by post-traumatic inflammation and fever 
caused by secondary infection (Thompson et al., 2003).  Temperature was 
tracked hourly because it is the variable at the heart of the normothermia 
protocol.  Even outside of this protocol, it is arguably one of the most important 
variables to track in TBI patients because of how detrimental hyperthermia is to 
patients following brain insult (Greer et al., 2008).  If uncontrolled, it can lead to 
longer ICU stays, poorer outcomes 6 months after discharge (as measured by 
modified Rankin Scale scores), and increased mortality (Greer et al., 2008; 
Thompson et al., 2003).  The source of the temperature measurement was 
recorded because after an insult to the brain, it is vital that the brain’s 
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temperature not rise too much, and different temperature sites can show values 
that underestimate the brain’s temperature with varying degrees (Mcilvoy, 2004).  
In cases of brain injury, it is essential to both use gold standard temperature sites 
and to keep the site consistent across consecutive measurements, and tracking 
temperature locations can raise awareness regarding inconsistencies in 
recording temperature.  Mannitol, 3% hypertonic saline, and, in extreme cases, 
23.4% hypertonic saline, are osmotic agents that are used to decrease 
intracranial pressure (Karamanos et al., 2014).  Their use indicates both that a 
patient was experiencing increased intracranial pressure and that a proactive 
attempt was made to reduce that pressure.   The Arctic Sun® temperature 
management system is used to cool patients who have spiked a fever.  A probe 
(in this case, a foley catheter) is used to gauge patient temperature, and the 
temperature of the water flowing through the machine’s reservoir is modulated in 
order to maintain the patient’s temperature at a set-point that is input by a nurse 
or physician.  The use of the Arctic Sun® system indicates persistent fever that 
cannot be controlled by Tylenol or normal cooling pads alone (Polderman & 
Herold, 2009).  The normothermia protocol is more aggressive in its use of the 
Arctic Sun® system to control fevers, and so it is expected that patient 
temperatures will be better maintained.  Tylenol is used to control fever.  
Recording its use allows comparison of the prevalence of its administration 
before and after the normothermia protocol was put in place.  Buspar (Buspirone) 
and Demerol (Meperidine) are used to reduce shivering, and recording their use 
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allows a measure of how common shivering is and how aggressively it is being 
managed.  Buspirone is used prophylactically at BMC and is administered when 
a patient has a fever for too long and is being more aggressively cooled (Boston 
Medical Center, 2012).  Meperidine is generally used in cases which are more 
difficult to control.  MAP, ICP, and CPP all need to be carefully managed to 
improve patient outcome.  ICP should remain normal (< 20) and the MAP should 
be high enough that an adequate CPP is obtained, but not so high that the 
patient become hypertensive.  The management of these values is not directly 
related to the normothermia protocol, but recording them allows for a picture of 
how well they are being managed and if the treatments involved in maintaining 
normothermia are affecting them in any way. 
Results 
All of the patients included in the final analysis were treated at Boston Medical 
Center between April 14, 2009 and November 28, 2013.  All patients in the 
control group (n = 51), who were not on the normothermia protocol, were treated 
between April 14, 2009 and December 10, 2010.  All patients in the case group 
(n = 29), who were on the normothermia protocol, were treated between June 2, 
2012 and November 28, 2013.   
Table 4 displays a summary of the most pertinent baseline data of the 
patients analyzed.  Each characteristic was coded into a categorical variable 
(yes/no for having that characteristic) and the control group was compared to the 
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case group using Fisher’s Exact Test.  The p-values are shown in the fourth 
column, and significant values are bolded.  The average age in the control group 
was 44.8 years, and the average age in the case group was 38.7 years; this age 
difference is not significant (p = 0.15).  The distribution of sexes remained similar 
between the two time periods (p = 0.61) even though the ratio of male to female 
patients rises from 2:1 in the  
control group to 3:1 in the case group. The two groups were fairly racially 
homogenous; only the number of white patients that were treated changed 
significantly from the control group to the case group (p = 0.01).  There was no 
Baseline Patient Information
Characteristic Controls Cases p-value 
Age (mean, range) 44.8 (18-77) 38.7 (17-85) 0.15 
Gender 
Male 
Female 
35 (69%) 
16 (31%) 
22 (76%) 
7 (24%) 
ref 
0.61 
Race 
White  
Black 
Hispanic 
Asian 
Other 
38 (74%) 
10 (20%) 
1 (2%) 
1 (2%) 
1 (2%) 
13 (45%) 
9 (31%) 
4 (14%) 
2 (7%) 
1 (3%) 
0.01 
0.28 
0.06 
0.30 
1.00 
Mechanism of Injury 
MVA 
Fall 
Pedestrian Hit 
Bicycle Hit 
GSW 
Assault 
Other 
18 (35%) 
12 (24%) 
6 (12%) 
3 (6%) 
4 (8%) 
4 (8%) 
4 (8%) 
8 (28%) 
9 (31%) 
5 (17%) 
1 (3%) 
3 (10%) 
1 (3%) 
2 (7%) 
0.62 
0.60 
0.52 
1.00 
0.70 
0.65 
1.00 
Transferred from 
Outside Hospitals 23 (45%) 4 (15%) 0.006 
Table 4 – An outline of all of the baseline characteristics extracted from each 
patient’s EMR.  p-values are calculated between groups for each characteristic. 
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significant change in the prevalence of any of the mechanisms of injury 
presented in Table 4 – they each occurred with a comparable frequency between 
the control and case groups. Interestingly, there were many more patients who 
came to BMC from outside hospitals in the control group than there were in the 
case group (p = 0.006).  
Table 5 shows the change in the control and the case group over the first 
7 days in the ICU.  The controls and the cases were similar across most 
measures.  The use of osmotics (mannitol, 3% hypertonic saline, and 23.4% 
hypertonic saline) for the management of intracranial pressure was more 
prevalent in the case group than the control group, partly because the ICPs of 
 
Beginning vs. End of Observation Period (# of patients)
Characteristic Controls Cases p-value 
Intubation Status 
Day 1 
Day 7 
51 (100%) 
26 (81%) 
29 (100%) 
21 (88%) 
1.00 
0.72 
Osmotic Use 
Day 1 
Day 7 
11 (22%) 
5 (16%) 
18 (62%) 
5 (21%) 
0.0006 
0.73 
Arctic Sun Use 
Day 1 
Day 7 
5 (10%) 
7 (22%) 
8 (28%) 
6 (25%) 
0.06 
1.00 
Tylenol Use 
Day 1 
Day 7 
29 (58%) 
29 (91%) 
21 (71%) 
19 (79%) 
0.23 
0.27 
Buspar Use 
Day 1 
Day 7 
0 (0%) 
1 (3%) 
7 (24%) 
7 (29%) 
0.0005 
0.02 
Demerol Use 
Day 1 
Day 7 
1 (2%) 
1 (3%) 
7 (24%) 
8 (33%) 
0.003 
0.003 
Table 5 – Proportions for both cases and controls on a number of measures on 
Day 1 and Day 7.  p-values are calculated between groups for each characteristic. 
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the patients in the case group were more difficult to manage.  As Table 6 shows, 
though, the ICPs of patients in the case group were not overall more poorly 
managed, so the neuro team’s response time and the osmotics used were 
effective in keeping patients’ ICPs in the proper range.  This is further reinforced 
by the data in Table 7, which show that there was no difference between the 
average ICP of the control group and the case group.  Buspar and Demerol use 
was also more significant in the case group as compared to the control group, 
both at 1 and 7 days.  This finding was expected.  While Buspar and Demerol 
were available for use before the normothermia protocol was put in place, and 
there were certainly situations in which they would have been useful, they were 
not commonly used.  The reason for this is not known.  It was expected to see a 
higher use of Arctic Sun® in the case group than the control group, but this was 
not so.  Both at day 1 and day 7, a similar number of patients received treatment 
with Arctic Sun®.  The difference between the number of patients receiving 
treatment was greater at day 1 (10% vs. 28%) than day 7 (22% vs. 24%), but the 
evidence against the null hypothesis (that the frequency of treatment with Arctic 
Sun® is the same in both groups) is weak and thus the difference is strictly non-
significant.   
The most important question of this work, though, is whether or not the 
temperature in the case group was better controlled than the temperature in the 
control group as a function of being on the normothermia protocol.  Table 7 
shows the aggregate number of data points that were collected for all of the 
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patients in each group.  As a reminder, the normothermic range is between 97.5o 
and 99.5oF.  The control group had a total of 3,385 temperature points and the 
case group had 2,533.  Of these, the control group was normothermic across 
39% of their measured values and the case group was normothermic across 
53% of their measures values.  This difference is very significant, with p = 
0.0001. 
Better temperature management is strongly believed to be linked to better 
outcome, and so both mortality and functional outcome are important to look at in 
addition to management.  As shown in Table 9, mortality in the case group was 
significantly lower both at the end of the first 7 days in the ICU (p = 0.01) and at 
the time of discharge from the hospital (p = 0.007). 
Average ICP, CPP, and MAP Over 7 Days 
Controls Cases p-value 
ICP 12.05 (n=29) 12.4 (n=20) 0.84 
CPP 73.9 (n=29) 77.5 (n=20) 0.08 
MAP 86.8 (n=50) 90.8 (n=29) 0.02 
Table 6 – This table shows the number of data points that fall within each range are shown for 
both cases and controls.  The p-value is calculated between-groups with the lower ICP range 
as the reference. 
 
Table 7 – This table shows the average ICP, CPP, and MAP for the control and case groups. 
The p-value is calculated between groups.  The reference groups are not shown. 
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ICP Management Over the First 7 Days in the ICU (data points) 
Controls Cases p-value 
ICP < 20 2329 2080 ref. 
ICP > 20 420 399 0.42 
Temperature Management Over the First 7 Days in the ICU (data points) 
x = the patient’s 
temperature Controls Cases p-value 
Temperature, 
97.5 < x < 99.5 1311 (39%) 1349 (53%) ref. 
Temperature, 
x < 97.5, x > 99.5 2074 (61%) 1184 (47%) 0.0001 
Mortality by the end of 7 ICU days and hospital stay (# of patients) 
Controls Cases p-value 
Expired at the 
end of day 7 10 0 0.01 
Expired at 
hospital discharge 17 2 0.007 
Modified Rankin Scale at Discharge and at Clinic (within groups) 
all patients 
included 
mRS ≤ 2 at discharge mRS ≤ 2 at clinic p-value 
Controls (n = 45) 2 9 0.049 
Cases (n = 27) 2 12 0.004 
Table 8 – The number of data points that fall within each range are shown for both cases and 
controls.  The p-value is calculated between groups with the normothermic range as the 
reference. 
Table 9 – This table shows the number of patients who expired by the 7th day and by the end 
of their hospital stay are shown for both cases and controls.  The p-value is calculated 
between groups. The reference groups are not shown. 
Table 10 – This table shows the number of patients with mRS values ≤ 2 at discharge and at 
clinic for both the cases and controls, for all patients, dead or alive.  The p-value is calculated 
within each group, comparing improvement between the two time points.  The reference 
groups are not shown. 
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In order to measure progression in functional outcome, modified Rankin Scale 
scores were extrapolated from patient discharge and clinic notes.  A modified 
Rankin Scale Score less than or equal to 2, indicating a slight disability, and 
characterized by the ability to look after one’s affairs despite being unable to 
carry out all previous activities, is the ultimate minimum goal for recovery.  All 
mRS data was coded into the categories of “≤ 2” and “≥ 3”.  Only patients for 
whom both discharge and clinic mRS were available were used for this analysis.  
6 patients were lost to follow-up in the control group, and 2 patients were lost to 
follow up in the case group.  Table 10 compares discharge mRS and clinic mRS 
for both controls and cases, taking into account the mRS scores of all patients 
(dead or alive), within each group.  
Enough patients in both the control and case groups experienced the 
desired improvement in their baseline mRS for the change to be statistically 
significant; .049 and .004 for the control group and case group, respectively.  The 
value is shown to three figures instead of two for the control group because it 
would appear statistically insignificant if it were rounded to two figures.  
Modified Rankin Scale at Discharge and at Clinic (between groups) 
all patients included Controls (n = 45) Cases (n = 27) p-value 
Discharge, mRS ≤ 2 2 2 0.63 
Clinic, mRS ≤ 2 9 12 0.03 
Table 11 – This table shows the number of patients with mRS values ≤ 2 at discharge and at 
clinic for both the cases and controls, for all patients, dead or alive.  The p-value is 
calculated between groups, comparing how the groups improved relative to one another.  
The reference groups are not shown. 
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Table 11 compares the mRS score improvement between the control and case 
groups.  As can be seen, patients leave the hospital in similar functional states (p 
= 0.63), but the patients in the case group experience a much higher 
improvement in their baseline status between when they are discharged and 
when they are seen in the clinic (p = 0.03).  Tables 10 and 11 show mRS data 
and p-values when all patients, dead and alive, are taken into account.  Tables 
12 and 13 show mRS data (in the same format as Tables 10 and 11) only for 
patients that are still alive at discharge.   
Modified Rankin Scale at Discharge and at Clinic (within groups) 
only living 
patients included 
mRS ≤ 2 at discharge mRS ≤ 2 at clinic p-value 
Controls (n = 28) 2 9 0.02 
Cases (n = 25) 2 12 0.004 
Modified Rankin Scale at Discharge and at Clinic (between groups) 
only living patients 
included 
Controls (n = 28) Cases (n = 25) p-value 
Discharge, mRS < 2 2 2 1.00 
Clinic, mRS < 2 9 12 0.27 
Table 12 – This table shows the number of patients with mRS values ≤ 2 at discharge and at 
clinic for both the cases and controls, for only those patients who were still alive.  The p-value 
is calculated within each group, comparing improvement between the two time points.  The 
reference groups are not shown. 
 
Table 13 – This table shows the number of patients with mRS values ≤ 2 at discharge and at 
clinic for both the cases and controls, for only those patients who were still alive.  The p-
value is calculated between groups, comparing how the groups improved relative to one 
another.  The reference groups are not shown. 
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This distinction is made because a substantially higher number of people died in 
the control group and compared to the case group, so it is possible that those 
deaths mask (in the statistical analysis) the improvement of those patients who 
are still alive.  Within both the control and case groups, patients experienced a 
significant change in their mRS scores between discharge and their clinic visits 
(p = 0.02 for controls and p = 0.004 for cases), as shown in Table 11.  As shown 
in Table 12, when the data is analyzed between groups, it does not appear as if 
there is any difference in the improvement of patients in the control group as 
compared to the patients in the case group.   
 
Discussion 
For the most part, the control group and the case group were very similar (see 
Table 4 for between-group p-values), but there were more whites in the control 
group than in the case group (p = 0.01), and more of the patients in the control 
group were transferred to Boston Medical Center from outside hospitals than in 
the case group.  It may seem intuitive that patients who are transferred from 
outside hospitals are likely to do more poorly at discharge and/or have a higher 
mortality due to delays in treatment, and there have been a number of studies 
confirming this intuition (Durairaj et al., 2003; Härtl et al., 2006; Joosse et al., 
2012; Rincon et al., 2010; Sampalis et al., 1997).  This is of concern because 
45% of the patients in the control group were transferred from outside hospitals, 
compared to only 15% in the case group (p = 0.006).  In recent years, there has 
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been a push for transporting patients directly to Level 1 trauma centers even if 
they are further away than the closest hospital not equipped to deal with severe 
trauma.  Part of the reasoning is that the extra transit time will not affect the 
patient as much as being brought to a hospital where they cannot be properly 
managed, and if the trauma is severe enough, the patient will need to be 
transferred to a Level 1 trauma center anyway; this increases the amount of time 
between the onset of the trauma and the start of the necessary treatment.  This 
requires better on-scene triaging to determine where the best place to send 
patients is.  Some of the patients in the control group were transferred by 
helicopter from as far as New Hampshire.  The decrease in the number of 
patients from outside hospitals in the case group could indicate that there are 
more Level 1 trauma centers readily available and that when a patient 
experiences a severe trauma in in the Boston area, they are more readily taken 
to Boston Medical Center than other hospitals.   
As shown in Table 9, 17 patients (33%) in the control group died by 
discharge, as compared to only 2 patients (7%) in the case group (p = 0.007).  
Within group analyses were conducted to determine whether the higher rate of 
outside hospital transfer in the control group had an effect on the outcome and 
mortality.  Of the 28 patients who were directly triaged at Boston Medical Center, 
8 died before discharge, and of the 20 who survived, 7 were discharged with an 
mRS of 4 and 9 were discharged with an mRS of 5.  Of the 23 patients who were 
transferred from outside hospitals, 9 died, and of the 14 who survived, 2 were 
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released with an mRS of 4 and 9 were released with an mRS of 5.  mRS scores 
of 2 and 3 were not taken into account for this analysis because they were equal 
between the two sub-groups.  The results of these analyses suggest that patients 
who were directly triaged and those who were transferred from outside hospitals 
had similar mortality rates after triage at Boston Medical Center (p = 0.55), and 
while there was a higher proportion of patients discharged with an mRS score of 
5 from the control group compared to the case group, this difference was not 
significant (p = 0.23).  This implies that, at least for the relatively limited sample 
that was examined in this study, transfer from an outside hospital did not 
significantly affect either mortality or outcome at discharge.    
Two of the most important variables to manage in brain trauma patients, 
ICP and CPP, were the same between the two groups.  Aggressive ICP 
management is very strongly advocated for in the literature, with the Brain 
Trauma Foundation (BTF) guidelines recommending that intervention be initiated 
when a patient’s ICP is above 20 mm Hg (Brain Trauma Foundation, 2007).  The 
control group and case group had average ICPs of 12.05 and 12.4, respectively 
(p = 0.84), which are well below the range at which ICP needs to be aggressively 
managed.  The case group did, however, undergo much more aggressive ICP 
management than the control group during the first day in the ICU, as indicated 
by the prevalent use of osmotics (62% of patients received them, compared to 
22% in the control group, p = 0.0006).  The use of osmotics leveled off by the 
seventh day in the ICU, though, with 21% of patients receiving them in the case 
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group compared to 16% in the control group (p = 0.73).  Osmotic use was more 
prevalent in the case group in general, but this may be due to a combination of a 
few factors, including an overall increase in severity of the injuries of patients in 
the case group and an increase in the number of patients that receive ICP bolts 
(p = 0.04, data not shown in any table).  Patients are not generally given 
osmotics unless their ICPs are being actively monitored using intracranial bolts, 
so the fact that there is a significantly higher proportion of patients in the case 
group who receive intracranial bolts could partially account for the increased use 
of osmotics in this group.  Even though osmotics are more regularly used in the 
case group, the ICPs of the patients in this group were very well managed, as 
evidenced by the low average ICP and the fact that patients in the control group 
and in the case group have a similar number of episodes of raised ICP, defined 
as ICP > 20 (p = 0.42; see Table 6).  Cerebral perfusion pressure, which the BTF 
recommends should be managed between 50-70 mm Hg (Brain Trauma 
Foundation, 2007), was another carefully monitored variable.  While there is 
evidence that maintaining CPP above 70 mm Hg may be beneficial for patient 
outcome (Rosner & Daughton, 1990), it is not a definite recommendation to do so 
because it generally requires the use of fluids and pressors (drugs which elevate 
arterial blood pressure mainly through activation of the sympathetic system) in an 
ICU setting, which can lead to adult respiratory system distress (ARDS) caused 
by volume overload and/or poor fluid management.  Both the control and case 
groups had average CPPs above 70, which did not differ significantly (p = 0.08).  
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Mean arterial pressure (MAP) is calculated by adding together CPP and ICP, so 
it can be affected by changes in either.  As such, it is likely not a variable that 
reveals a lot of information in this scenario.  The control group had a statistically 
significantly lower MAP than the case group (controls = 90.8 mm Hg, cases = 
86.8 mm Hg, p = 0.02), but this difference can be explained in terms of the 
between-group differences in ICP and CPP, which themselves were not 
significant.  The average MAP for the cases is 4 mm Hg higher than the average 
MAP for the controls, but the cases also have an average ICP that is .4 mm Hg 
higher than the controls and an average CPP that is 3.6 mm Hg higher than the 
controls.  Because MAP is additive, these two differences compound, and while 
the final difference is statistically significant, it is unlikely that it is clinically 
significant.   
Taken together, the data presented in the previous paragraphs suggest 
that, aside from a significantly higher proportion of white patients in the control 
group as compared to the case group, the two groups observed in this analysis 
are equivalent.  Even though there were significantly more patients admitted from 
outside hospitals in the control group, it was demonstrated that, contrary to what 
is generally observed in studies involving larger sample sizes, there was neither 
an increased incidence of death during the hospital stay nor a poorer functional 
outcome at clinic in this group.  This is important to consider when examining the 
main variable of interest, temperature, as well as mortality and functional 
outcome at the clinic visit.   
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 As shown in Table 8, the difference in the number of temperature points 
recorded as normothermic between the control group and the case group was 
very significant (p = 0.004), with the case group spending more time within the 
normothermic range.  This observation is even more powerful in light of the fact 
that the average temperature across the first 7 ICU days for all patients is 
actually the same (99.27oF for the control group, and 99.29oF for the case group, 
p = 0.94).  The standard deviation for the control group was 1.22oF while only 
.71oF for the case group.  This indicates that while the average temperatures for 
the two groups were almost identical, the temperature of the patients in the 
control group was more tightly regulated.  Both of these two temperatures are in 
the upper end of the normothermic range, so less deviation from the mean is 
desirable.  Taken together, these two observations suggest that the 
normothermia protocol is indeed successful in regulating patient temperatures, 
both by keeping them within the normothermic range more effectively and by 
keeping them more closely around a normothermic mean than regular 
temperature control.       
When taking into account all of the patients in the study, the case group’s 
patients showed significantly better functional improvement between discharge 
and their clinic visit, as shown in Table 11.  Due to the large difference in 
mortality between the two groups (more controls died during their hospital stay, p 
= 0.007), though, looking at mRS improvement while including all patients may 
be misleading.  Patients who are dead are assigned an mRS of 6, so they are in 
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the “mRS ≥ 3” category, along with all of the patients with an mRS of 3, 4, and 5.  
The reason that this may slightly bias the data is because patients with an mRS 
of 6 stay there – there is no room for improvement.  As a result, a large 
proportion of the control group’s constituents are locked in on the “mRS ≥ 3” with 
no chance of recovery.  As such, the test is not strictly measuring how much 
patients improve in the months after discharge; since it takes all patients into 
account, this statistic better serves to answer the question of how patients do 
from when they are triaged to when they are seen in the clinic.  The result, as 
previously stated, shows that patients in the case group are more likely to leave 
the hospital and recover to the point that they can do most of what they used to.  
This is a good result, but it does not show the whole picture.  The data shown in 
Table 13 are intended to answer the question, “If you survive in the hospital, how 
likely are you to recover to the point that you can do most of what you were 
previously able to do?”  The answer, it seems, is that patients in both the control 
group and the case group are equally as likely to recover to that point (p = 0.27).  
This is an important distinction.  When looking at all patients, those in the case 
group were more likely to survive and recover to a reasonable functional level 
after a TBI, but when looking only at patients who were alive at discharge, 
patients in the control group and the case group were just as likely to recover to a 
reasonable functional level.  This implies that aggressive temperature 
management may be involved in keeping patients alive during the hospital stay 
so that they may be discharged to a rehabilitation facility, but it may not be 
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involved in actually improving the degree of their recovery.  This is a great first 
step, and the data do not exclude the ability of aggressive normothermic 
temperature management to also be involved in improving functional outcome, 
although this effect was not seen here.  While the normothermia protocol was 
shown to be effective, 47% of the total temperature points collected for the case 
group were still not within the normothermic range (compared to 61% for the 
controls).  It is possible that the benefits of normothermia will be even greater 
when techniques and equipment improve to the point that patients can be kept 
normothermic for a higher proportion of time, and perhaps, eventually indefinitely.   
The most promising conclusion, perhaps, is that because the control 
group and the case group were almost identical in terms of demographics, 
method of injury, and management of cerebral perfusion, with only the 
temperature management being very different between the two groups, at least a 
part of the effect seen can be attributed to aggressive temperature management 
under the normothermia protocol.  There was a significantly lower incidence of 
death in the case group, and when taking into account all of the patients in the 
study, the case group did significantly better in terms of functional outcome at the 
time of their first clinic visit.   
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Limitations 
While the data do suggest a benefit of normothermia on patient outcome, this 
study has a number of limitations.  Being a retrospective study, patient data was 
not recorded at the time of treatment with the intent of being later analyzed in the 
way it was analyzed here.  Most notably, for temperature, many potential data 
points were missed because temperature was recorded inconsistently (i.e., every 
2 or 3 hours instead of hourly, during many patients’ stays).  A prospective study 
would ensure that temperature was recorded consistently.  Regarding patient 
care, in the time that passed between when the patients in the control group 
were seen and when the patients in the case group were seen, a neuro ICU team 
was established, and so care was likely overall more effective for patients in the 
case group.  Additionally, due to the fact that mRS was extrapolated from 
discharge and clinic notes, it is possible that the extracted scores are not fully 
reflective of what would have been calculated for the patient in person.   
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Conclusion 
In this study, aggressive temperature management under the induced 
normothermia protocol was associated with a decrease in mortality and a higher 
probability of achieving a good functional outcome when evaluating patients from 
the time of hospital admission to their clinic visit.  If implemented on a large 
scale, induced normothermia could reduce the overall costs of severe TBIs by 
reducing the large indirect costs of TBI care at the price of an increase in the 
direct costs.  As this study is retrospective, though, there are a number of 
uncontrolled factors that could have led to the overestimation of the effect of the 
treatment.  Regardless, there is a need for high-quality prospective randomized 
controlled studies assessing the efficacy of aggressive induced normothermia in 
reducing mortality and improving functional outcomes as compared to regular 
fever management.     
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